GlaxoSmithKline has set out a two-year plan to split itself in two after missing its earnings targets in full year results and predicting a decline in earnings this year.
Pfizer kicked off big pharma’s final results season with a disappointing readout that sent its share price ticking down, with breast cancer drug Ibrance missing sales expectations and off-p
Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.
High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug